Next Generation Anti-Tuberculosis Drugs
The research group Next-Gen-BTZ is integrated into the structural unit Transfer Group Antiinfectives.
The group focuses on the rational design of new generations of antibiotic ingredients against Mycobacterium tuberculosis, the causative pathogen of tuberculosis. In addition, yet unknown metabolic pathways are studied on a molecular level in order to understand and predict the efficacy and interactions of antituberculosis drug candidates currently being in clinical development.
The research group Next-Gen-BTZ is funded by the Free State of Thuringia with means of the European Social Fund.
Dr. Sebastian Schieferdecker
Phone: +49 3641 532-1350 Email: email@example.com